Literature DB >> 30139761

Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF.

Vyala Hanumanthareddy Chaithra1, Shancy Petsel Jacob1, Chikkamenahalli Lakshminarayana Lakshmikanth1, Mosale Seetharam Sumanth1, Kandahalli Venkataranganayaka Abhilasha1, Chu-Huang Chen2, Anita Thyagarajan3, Ravi P Sahu3, Jeffery Bryant Travers3, Thomas M McIntyre4, Kempaiah Kemparaju1, Gopal Kedihithlu Marathe5,6.   

Abstract

Platelet-activating factor (PAF) is a potent inflammatory mediator that exerts its actions via the single PAF receptor (PAF-R). Cells that biosynthesize alkyl-PAF also make abundant amounts of the less potent PAF analogue acyl-PAF, which competes for PAF-R. Both PAF species are degraded by the plasma form of PAF acetylhydrolase (PAF-AH). We examined whether cogenerated acyl-PAF protects alkyl-PAF from systemic degradation by acting as a sacrificial substrate to enhance inflammatory stimulation or as an inhibitor to dampen PAF-R signaling. In ex vivo experiments both PAF species are prothrombotic in isolation, but acyl-PAF reduced the alkyl-PAF-induced stimulation of human platelets that express canonical PAF-R. In Swiss albino mice, alkyl-PAF causes sudden death, but this effect can also be suppressed by simultaneously administering boluses of acyl-PAF. When PAF-AH levels were incrementally elevated, the protective effect of acyl-PAF on alkyl-PAF-induced death was serially decreased. We conclude that, although acyl-PAF in isolation is mildly proinflammatory, in a pathophysiological setting abundant acyl-PAF suppresses the action of alkyl-PAF. These studies provide evidence for a previously unrecognized role for acyl-PAF as an inflammatory set-point modulator that regulates both PAF-R signaling and hydrolysis.
Copyright © 2018 Chaithra et al.

Entities:  

Keywords:  PAF acetylhydrolase; PAF analogue; PAF-like lipids; platelet aggregation

Mesh:

Substances:

Year:  2018        PMID: 30139761      PMCID: PMC6210909          DOI: 10.1194/jlr.M085704

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  55 in total

1.  Synthesis of 1-acyl-2-[3H]acetyl-SN-glycero-3-phosphocholine, a structural analog of platelet activating factor, by vascular endothelial cells.

Authors:  H W Mueller; M U Nollert; S G Eskin
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

Review 2.  To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase.

Authors:  Gopal Kedihitlu Marathe; Chaitanya Pandit; Chikkamenahalli Lakshminarayana Lakshmikanth; Vyala Hanumanthareddy Chaithra; Shancy Petsel Jacob; Cletus Joseph Michael D'Souza
Journal:  J Lipid Res       Date:  2014-05-23       Impact factor: 5.922

3.  Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein.

Authors:  Aaron V Pontsler; Andy St Hilaire; Gopal K Marathe; Guy A Zimmerman; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2002-01-23       Impact factor: 5.157

Review 4.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

5.  Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.

Authors:  Rachel N Gomes; Fernando A Bozza; Rodrigo T Amâncio; André M Japiassú; Rosa C S Vianna; Andréa P Larangeira; Juliana M Gouvêa; Marcela S Bastos; Guy A Zimmerman; Diana M Stafforini; Stephen M Prescott; Patrícia T Bozza; Hugo C Castro-Faria-Neto
Journal:  Shock       Date:  2006-07       Impact factor: 3.454

6.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 7.  Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice.

Authors:  S Ishii; T Shimizu
Journal:  Prog Lipid Res       Date:  2000-01       Impact factor: 16.195

8.  Platelet-activating factor biosynthesis induced by various stimuli in human HaCaT keratinocytes.

Authors:  J B Travers; K A Harrison; C A Johnson; K L Clay; J G Morelli
Journal:  J Invest Dermatol       Date:  1996-07       Impact factor: 8.551

9.  Synthesis of platelet-activating factor by human blood platelets and leucocytes. Evidence against selective utilization of cellular ether-linked phospholipids.

Authors:  A Sturk; M C Schaap; A Prins; J W ten Cate; H van den Bosch
Journal:  Biochim Biophys Acta       Date:  1989-12-08

Review 10.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation.

Authors:  Takao Shimizu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

View more
  7 in total

1.  CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients.

Authors:  Mengying Ke; Liqing Kang; Ling Wang; Shu Yang; Yajun Wang; Haiyan Liu; Chunyan Gu; Hongming Huang; Ye Yang
Journal:  J Hematol Oncol       Date:  2021-06-09       Impact factor: 17.388

2.  Thermal Burn Injury Generates Bioactive Microvesicles: Evidence for a Novel Transport Mechanism for the Lipid Mediator Platelet-Activating Factor (PAF) That Involves Subcellular Particles and the PAF Receptor.

Authors:  Langni Liu; Katherine E Fahy; Azeezat A Awoyemi; Pariksha Thapa; Lisa E Kelly; Jay Chen; Ji C Bihl; David R Cool; Yanfang Chen; Christine M Rapp; R Michael Johnson; Jeffrey B Travers
Journal:  J Immunol       Date:  2020-05-20       Impact factor: 5.426

Review 3.  Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.

Authors:  Renata de Freitas Saito; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

Review 4.  Plasmalogenic Lipid Analogs as Platelet-Activating Factor Antagonists: A Potential Novel Class of Anti-inflammatory Compounds.

Authors:  Pu Rong; Jie-Li Wang; Angelina Angelova; Zakaria A Almsherqi; Yuru Deng
Journal:  Front Cell Dev Biol       Date:  2022-04-12

5.  A novel Danshensu/tetramethylpyrazine protects against Myocardial Ischemia Reperfusion Injury in rats.

Authors:  Jinghao Wang; Kai Fan; Cong He; Qingyang Wang; Qianhui Zhang; Wei Huang
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

Review 6.  Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Isabella Wimmer; Johannes Berger
Journal:  Neurobiol Dis       Date:  2020-08-28       Impact factor: 5.996

Review 7.  New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.

Authors:  Jeffrey B Travers; Joyce G Rohan; Ravi P Sahu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.